{
    "clinical_study": {
        "@rank": "36673", 
        "arm_group": [
            {
                "arm_group_label": "d-Amphetamine Transdermal System", 
                "arm_group_type": "Active Comparator", 
                "description": "d-Amphetamine Transdermal System"
            }, 
            {
                "arm_group_label": "Placebo patch", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo patch"
            }
        ], 
        "brief_summary": {
            "textblock": "This study will evaluate safety and efficacy of d-Amphetamine Transdermal System for the\n      treatment of Attention Deficit Hyperactivity Disorder in children and adolescents."
        }, 
        "brief_title": "Study to Evaluate Safety & Efficacy of d-Amphetamine Transdermal System Compared to Placebo in Children & Adolescents With ADHD", 
        "completion_date": {
            "#text": "March 2013", 
            "@type": "Actual"
        }, 
        "condition": "Attention Deficit Hyperactivity Disorder", 
        "condition_browse": {
            "mesh_term": [
                "Attention Deficit Disorder with Hyperactivity", 
                "Hyperkinesis"
            ]
        }, 
        "detailed_description": {
            "textblock": "The study will consist of a four-week screening period, a 3-day wash-out period (if\n      applicable), a five-week open-label, step-wise dose optimization period and two-week double\n      blind randomized crossover treatment period with weekly classroom assessments and a safety\n      follow-up by telephone 7 - 10 days after last dose of study drug."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Gender:  Male or female;\n\n          -  Age:  Between 6 &17 years of age, inclusive;\n\n          -  Race: All eligible;\n\n          -  Females of child-bearing potential must agree to practice a clinically accepted\n             method of contraception during the study & for at least one month prior to study\n             dosing & one month following completion of the study. Acceptable contraceptive\n             methods include abstinence, oral contraception, surgical sterilization (bilateral\n             tubal ligation, bilateral oophorectomy or hysterectomy), intrauterine device, or\n             diaphragm in addition to spermicidal foam & condom on male partner, or systemic\n             contraception [e.g. Norplant System];\n\n          -  Must meet Diagnostic & Statistical Manual of Mental Disorders, 4th edition - Text\n             Revision criteria for a primary diagnosis of ADHD combined,  predominately\n             hyperactive impulsive type, or predominately inattentive type;\n\n          -  The screening & baseline visit ADHD-RS-IV total score must be 90% or greater relative\n             to the general population of children by age & gender;\n\n          -  Must be able to wear a patch for 9 hours. Parent or caregiver must be present to\n             apply & remove the patches & maintain the used & unused patches in a secure\n             controlled area of the home;\n\n          -  Must be functioning at an age appropriate level intellectually as determined by an\n             intelligence quotient of \u226580 on the Wechsler Abbreviated Scale of Intelligence II\u2122,\n             vocabulary & matrix reasoning components;\n\n          -  Must have the ability to complete PERMP assessment;\n\n          -  Have parental consent & written or verbal assent from the subject;\n\n          -  Subject & parent(s)/caregiver are willing & able to comply with all the protocol\n             requirements & parent(s) or caregiver must be able to provide transportation for the\n             subject to & from the analog classroom sessions.\n\n        Exclusion Criteria:\n\n          -  Has blood pressure & pulse outside the 95th percentile for age & gender;\n\n          -  Is a known non-responder to amphetamine treatment;\n\n          -  Has a documented allergy, intolerance, or hypersensitivity to amphetamine;\n\n          -  Is currently taking an ADHD medication that is providing symptom control with no\n             residual impairment at home or school & has acceptable tolerability & adherence;\n\n          -  Has a recent history (within the past 6 months) of suspected substance abuse or\n             dependence disorder (including nicotine);\n\n          -  Has a history of seizures during the last 2 years (exclusive of infantile febrile\n             seizures), a tic disorder (exclusive of transient tic disorder), a current diagnosis\n             and/or a family history of Tourette's Disorder. Mild medication-induced tics are not\n             exclusionary;\n\n          -  Has any psychiatric disorder that could interfere with study participation or the\n             safety of the subject or other participants, such as conduct disorder or oppositional\n             defiant disorder with a history of prominent aggressive outbursts. Children meeting\n             CD or ODD but without prominent aggression will be allowed to enroll at the\n             discretion of the investigator;\n\n          -  Has Autism or Asperger's Disorder;\n\n          -  Has a family history (first degree relatives) of sudden cardiac death;\n\n          -  Has current controlled (requiring medication) or uncontrolled comorbid psychiatric\n             conditions such as post traumatic stress disorder, psychosis, bipolar illness, severe\n             obsessive compulsive disorder, severe depressive or severe anxiety disorder,\n             considered a suicide risk, has previously attempted suicide, has prior history of or\n             is currently demonstrating suicidal ideation;\n\n          -  Has a history of abnormal thyroid function;\n\n          -  Has BMI for age greater than 95th percentile per CDC BMI-for-gender specific charts;\n\n          -  Has a known history of symptomatic cardiovascular disease, advance arteriosclerosis,\n             structural cardiac abnormality, cardiomyopathy, serious heart rhythm abnormalities,\n             coronary artery disease, or other serious cardiac problems that may place them at\n             increased vulnerability to the sympathomimetic effects of a stimulant drug;\n\n          -  Has any skin abnormality present at the potential application site that is likely to\n             be aggravated by the study drug (i.e., infection, rash, atrophy, excessive fragility\n             or dryness, any cut or abrasion, or tattoo);\n\n          -  Has a history of hypersensitivity, allergy to topical medication, preparation, or\n             adhesive dressings;\n\n          -  Has concurrent chronic or significant acute illnesses (such as severe allergic\n             rhinitis or an infectious process requiring antibiotics, unless expected to resolve\n             or has resolved by Day 0) disability or any unstable medical condition  that in the\n             investigator's opinion would lead to difficulty complying with the protocol\n             requirements;\n\n          -  Has used any investigational drug within 30 days of the screening visit;\n\n          -  Has a history of physical, sexual, or emotional abuse in the last year;\n\n          -  Has a medical history of Hepatitis A, B,C or HIV;\n\n          -  Has positive urine drug screen."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "17 Years", 
            "minimum_age": "6 Years"
        }, 
        "enrollment": {
            "#text": "106", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "October 15, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01711021", 
            "org_study_id": "N25-006"
        }, 
        "intervention": [
            {
                "arm_group_label": "d-Amphetamine Transdermal System", 
                "description": "Patches will be worn for 9 hours every day. After 9 hours the patch will be removed. Every day a new patch will be applied.", 
                "intervention_name": "d-Amphetamine Transdermal System", 
                "intervention_type": "Drug", 
                "other_name": [
                    "d-Amphetamine", 
                    "Amphetamine"
                ]
            }, 
            {
                "arm_group_label": "Placebo patch", 
                "description": "Patches will be worn for 9 hours every day. After 9 hours the patch will be removed. Every day a new patch will be applied.", 
                "intervention_name": "Placebo patch", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Placebo", 
                    "Sham treatment"
                ]
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Amphetamine", 
                "Dextroamphetamine"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "ADHD", 
        "lastchanged_date": "April 1, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Miami", 
                    "country": "United States", 
                    "state": "Florida", 
                    "zip": "33199"
                }, 
                "name": "Center for Children and Families"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Double-Blind, Placebo-Controlled, Crossover, Laboratory Classroom Study to Evaluate the Safety and Efficacy of d-Amphetamine Transdermal Drug Delivery System (d-ATS) Compared to Placebo in Children and Adolescents With ADHD", 
        "overall_official": {
            "affiliation": "Not Affiliated", 
            "last_name": "James Waxmonsky, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "March 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Change from baseline in total SKAMP Scores", 
            "safety_issue": "No", 
            "time_frame": "Measured weekly during a  two-week double-blind treatment period"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01711021"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Noven Pharmaceuticals, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Noven Pharmaceuticals, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}